#### THE UNIVERSITY OF MICHIGAN REGENTS COMMUNICATION

# ACTION REQUEST

Subject: License Agreement between the University of Michigan and Sublime, LLC

Action Requested: Approval of License Agreement

#### Preamble:

A statutory conflict of interest situation was identified by the Office of Technology Transfer while reviewing the technology transfer agreement that then triggered a review by the UMOR Conflict of Interest Review Committee. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by this Committee and agreed to by the parties involved in this plan.

This proposed license agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Professor Max Shtein is an employee of the University of Michigan ("University") and a partial owner of Sublime, LLC. The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

## Background:

Dr. Max Shtein, a Professor in the Department of Materials Science & Engineering, is the partial owner of a for-profit company called Sublime, LLC (the "Company"). The Company was formed recently to commercialize next generation organic jet vapor printing technology and desires to license from the University of Michigan the University's rights associated with the following technologies:

UM OTT File No. 6705, entitled: "Method to Enhance Bioavailability of Organic Small Molecule Medicines" (Inventors: Max Shtein, Olga Shalev, Geeta Mehta, Shreya Raghavan)

UM OTT File No. 7570, entitled: "Precision Bio-Chemotronic Devices and Systems" (Inventors: Max Shtein, Olga Shalev)

UM OTT File No. 2018-445, entitled: "Process and Apparatus for Creating Pharmaceutical Cocrystals" (Inventors: Max Shtein, Siddharth Suresh Borsadia)

The Office of Technology Transfer selected the Company as a University partner and negotiated the terms of the proposed Agreement in accordance with University policy and its accepted licensing principles.

## Parties to the Agreement:

The Regents of the University of Michigan and Sublime, LLC

# Agreement Terms Include:

Agreement terms include granting the Company an exclusive license with the right to grant sublicenses. The Company will pay a royalty on sales and reimburse patent costs. The University may receive equity in the Company, along with the right to purchase more equity.

The University will retain ownership of the licensed technologies and may continue to further develop and use them internally. No use of University services or facilities, nor any assignment of University employees, is obligated or contemplated under the Agreement. Standard disclaimers of warrantees and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

# Pecuniary Interest:

The pecuniary interests of Dr. Shtein arise from his ownership interest in Sublime, LLC.

# Net Effect:

The Office of Technology Transfer has negotiated and finalized the terms of a worldwide exclusive license agreement for patents related to UM OTT File Nos. 6705, 7570, and 2018-445 for all fields of use. Sublime, LLC will obtain use and commercialization rights to the above listed University technology.

## Recommendations:

This matter has been reviewed and approved by the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I <u>recommend</u> that the Board of Regents approve the Agreement between the University and Sublime, LLC.

Respectfully submitted,

S. Jack Hu Vice President for Research

May 2019